A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding

Table 4

Comparison between the non-high-dose and high-dose PPI after case-controlled matching.

Characteristic	Non-high-dose group (𝑛=44)	High-dose group (𝑛=44)	𝑃 value
Age (years)	66.2±12.9	61.7±13.8	0.121
Female gender, 𝑛 (%)	11 (25)	12 (27.3)	0.808
Creatinine (mg/dL)	2.3±2.3	2.6±2.8	0.615
Hb (g/L)	93.3±25.3	92.5±28.7	0.897
Platelet (×10^9/L)	170.4±86.2	189.2±82.1	0.297
Use of NSAIDs, 𝑛 (%)	3 (6.8)	2 (4.5)	0.696
Use of aspirin, 𝑛 (%)	4 (9.1)	5 (11.4)	0.725
Use of clopidogrel, 𝑛 (%)	3 (6.8)	4 (9.1)	0.694
Use of warfarin, 𝑛 (%)	1 (2.3)	2 (4.5)	0.557
Coexisting illness, 𝑛 (%)
CKD III, IV/V	19/6	13/7	0.410
COPD	1	0	0.315
CAD	6	10	0.269
DM	12	14	0.640
CVA	12	7	0.195
Liver cirrhosis	10	8	0.597
Shock oat presentation	24	28	0.386
Rockall score	6.1±1.4	6.4±1.5	0.387
Time to endoscope (hours)	18.3±23.9	13.6±17.2	0.299
PRBC BT (mL)	1369.3± 1496.5	1596.6±1914.0	0.537
Forrest classification Ia/Ib/IIa/IIb/IIc/III	2/28/1/13	1/28/4/11	0.513
Time to oral PPI (days)	4.5±4.4	6.9±4.8	0.016^*
Rebleeding, 𝑛 (%)	8 (18.2)	7 (15.9)	0.777
Surgery, 𝑛 (%)	0	0	1.000
Hospital stay (days)	12.1±17.2	14.3±13.5	0.505
Mortality, 𝑛 (%)	5 (11.4)	3 (6.8)	0.359
Bleeding related/other causes	3/2	3/0

Hb: hemoglobin, NSAID: nonsteroidal anti-inflammatory drug, CKD: chronic kidney disease, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton-pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. ^*𝑃<0.05.